<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

MLN 9708 - Ixazomib citrate

產(chǎn)品貨號

Axon 2557 CAS [1201902-80-8] MF C20H23BCl2N2O9MW 517.12 Purity: 99% Soluble in DMSO Description Citrate prodrug of MLN 2238 (Ixazomib; Axon 2556), a selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 9708 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. Approved by the FDA in November 2015 for multiple myeloma treatment. KEYWORDS: MLN 9708 | supplier | Proteasome inhibitor | Ixazomib citrate | MLN9708 | CAS [1201902-80-8] | Ubiquitin | Proteasome 20S | Inhibitor | MLN2238 | MLN 2238 | prodrug | β5 subunit | B-cell lymphoma | FDA approved

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

MLN 9708 - Ixazomib citrate

Based on 273 reference(s) in Google Scholar 10 10 273

Axon 2557

CAS [1201902-80-8]

MF C20H23BCl2N2O9
MW 517.12

Purity: 99%
Soluble in DMSO

MLN 9708

Description

Citrate prodrug of MLN 2238 (Ixazomib; Axon 2556), a selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 9708 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. Approved by the FDA in November 2015 for multiple myeloma treatment.

E Kupperman et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer Res. 2010 Mar 1;70(5):1970-80.

JJ Gu et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive….Anticancer Drugs. 2013 Nov;24(10):1030-8.

N Shah et al. Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma. Exp. Opin. Orph. Drugs (2016), 4(1), 105-113.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Signaling & Oncology Immunology Pain & Inflammation Ubiquitin EC 3.4 Proteasome 20S

Citrate prodrug of MLN 2238, selective and reversible 20S proteasome inhibitor

Chemical name

4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

Parent CAS No.

[1201902-80-8]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>